HP 101

Drug Profile

HP 101

Latest Information Update: 13 Aug 2002

Price : $50

At a glance

  • Originator SYGNIS Pharma
  • Class Antibacterials
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 13 Aug 2002 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 21 May 2001 No-Development-Reported for Bacterial infections in USA (Unknown route)
  • 11 Apr 2001 Trega Biosciences has been acquired by LION bioscience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top